Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBTargeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Mirdametinib Scores FDA Priority Review in Neurofibromatosis …
WEBAug 28, 2024 — The FDA has granted priority review to the new drug application of mirdametinib (formerly PD-0325901) in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
The Promise of IL-21 Engineered NK Cells in Glioblastoma Treatment
WEBAug 30, 2024 — Glioblastoma (GBM) is among the most aggressive and deadly forms of brain cancer, with current treatment options offering limited success. While standard therapies consist of surgery, radiation, and chemotherapy, they often fail to provide long-term control of the disease, leaving experts searching for more effective treatment strategies. 1 One avenue being investigated is the potential of the ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 — After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
FDA Acknowledges BLA of Zolbetuximab in HER2–, CLDN18.2
WEBMay 31, 2024 — The FDA has acknowledged the resubmitted biologics license application (BLA) for zolbetuximab (Vyloy) as a first-line treatment for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive. Zolbetuximab is a first-in-class investigational CLDN18.2-targeted monoclonal antibody.
DLBCL - targetedonc.com
WEBAn ongoing phase 1a/1b trial is set to evaluate NX-1607-101, an oral small-molecule inhibitor of casitas B-lineage lymphoma B designed to enhance innate and adaptive immune responses and demonstrate antitumor activity and long-term survival in patients with persistent lymphoma including those with diffuse large B-cell lymphoma.
Nadofaragene Firadenovec Now Fully Available for BCG …
WEBJan 16, 2024 — Nadofaragene firadenovec (Adstiladrin) is the first and only intravesical gene therapy to be approved by the FDA for adult patients with non-muscle invasive bladder cancer (NMIBC) who no longer respond to standard therapy.
FDA Grants Priority Review to BLA of Afami-cel in Synovial Sarcoma
WEBFeb 2, 2024 — Afami-cel is an engineered T-cell receptor therapy which works to target the MAGE-A4 protein among patients with synovial sarcoma. This type of sarcoma makes up about 5%-10% of all soft tissue sarcomas, with around 13,400 new cases diagnosed each year in the United States.2 The outlook for patients with synovial sarcoma often is poor, with only 20% of patients survival for 5 years after ...
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 — Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
Jordyn Sava - Targeted Oncology
WEBJordyn Sava is an editor for Targeted Oncology. ... Isa-KRd showed deep responses, high MRD negativity rates, and manageable safety in patients with newly diagnosed, transplant-eligible multiple myeloma, as per interim analysis of the IFM2020-02 MIDAS study.